162 related articles for article (PubMed ID: 32427034)
21. Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy.
Schenk S; McCarthy PM; Starling RC; Hoercher KJ; Hail MD; Ootaki Y; Francis GS; Doi K; Young JB; Fukamachi K
J Thorac Cardiovasc Surg; 2004 Jul; 128(1):38-43. PubMed ID: 15224019
[TBL] [Abstract][Full Text] [Related]
22. Low- and High-renin Heart Failure Phenotypes with Clinical Implications.
Pavo N; Goliasch G; Wurm R; Novak J; Strunk G; Gyöngyösi M; Poglitsch M; Säemann MD; Hülsmann M
Clin Chem; 2018 Mar; 64(3):597-608. PubMed ID: 29138270
[TBL] [Abstract][Full Text] [Related]
23. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
Benedict CR; Shelton B; Johnstone DE; Francis G; Greenberg B; Konstam M; Probstfield JL; Yusuf S
Circulation; 1996 Aug; 94(4):690-7. PubMed ID: 8772689
[TBL] [Abstract][Full Text] [Related]
25. Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF.
Palazzuoli A; Ruocco G; Beltrami M; Nuti R; Cleland JG
Clin Res Cardiol; 2018 Jul; 107(7):586-596. PubMed ID: 29532155
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
[TBL] [Abstract][Full Text] [Related]
27. Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure.
Tsutamoto T; Sakai H; Tanaka T; Fujii M; Yamamoto T; Wada A; Ohnishi M; Horie M
Circ J; 2007 Jun; 71(6):915-21. PubMed ID: 17526990
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations.
Groenning BA; Nilsson JC; Sondergaard L; Kjaer A; Larsson HB; Hildebrandt PR
Eur J Heart Fail; 2001 Dec; 3(6):699-708. PubMed ID: 11738222
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction.
Hage C; Bjerre M; Frystyk J; Gu HF; Brismar K; Donal E; Daubert JC; Linde C; Lund LH
Am J Cardiol; 2018 Jun; 121(12):1558-1566. PubMed ID: 29622288
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction.
Koller L; Kleber ME; Brandenburg VM; Goliasch G; Richter B; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer TB; Delgado G; Tomaschitz A; Pilz S; Berger R; Mörtl D; Hülsmann M; Pacher R; März W; Niessner A
Circ Heart Fail; 2015 Nov; 8(6):1059-67. PubMed ID: 26273098
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
Rouleau JL; Packer M; Moyé L; de Champlain J; Bichet D; Klein M; Rouleau JR; Sussex B; Arnold JM; Sestier F
J Am Coll Cardiol; 1994 Sep; 24(3):583-91. PubMed ID: 7915733
[TBL] [Abstract][Full Text] [Related]
33. Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure: relation with ventricular stiffness and outcome.
Ruocco G; Evangelista I; Franci B; Lucani B; Martini S; Nuti R; Palazzuoli A
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):81-90. PubMed ID: 30540645
[TBL] [Abstract][Full Text] [Related]
34. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
35. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
36. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
[TBL] [Abstract][Full Text] [Related]
39. Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure.
Sasaki T; Kubo T; Komamura K; Nishikimi T
J Cardiol; 1999 Jun; 33(6):317-25. PubMed ID: 10396705
[TBL] [Abstract][Full Text] [Related]
40. Comparable prognostic impact of BNP levels among HFpEF, Borderline HFpEF and HFrEF: a report from the CHART-2 Study.
Kasahara S; Sakata Y; Nochioka K; Yamauchi T; Onose T; Tsuji K; Abe R; Oikawa T; Sato M; Aoyanagi H; Miura M; Shiroto T; Takahashi J; Miyata S; Shimokawa H;
Heart Vessels; 2018 Sep; 33(9):997-1007. PubMed ID: 29569034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
